Hanall Biopharma Co.,Ltd
009420.KSFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
104
Cost of Revenue
49
Gross Profit
55
Gross Margin
52.8%
Operating Income
0
Operating Margin
0.2%
Net Income
-1
Net Margin
-1.3%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
3
EBITDA Margin
2.4%
2023
12/31/2023
Revenue
101
Cost of Revenue
45
Gross Profit
56
Gross Margin
55.6%
Operating Income
2
Operating Margin
2.3%
Net Income
3
Net Margin
2.6%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
5
EBITDA Margin
4.9%
2022
12/31/2022
Revenue
82
Cost of Revenue
36
Gross Profit
46
Gross Margin
56.3%
Operating Income
1
Operating Margin
1.4%
Net Income
0
Net Margin
0.2%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
4
EBITDA Margin
4.6%
2021
12/31/2021
Revenue
76
Cost of Revenue
31
Gross Profit
45
Gross Margin
59.4%
Operating Income
8
Operating Margin
9.9%
Net Income
7
Net Margin
8.8%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
9
EBITDA Margin
11.3%
2020
12/31/2020
Revenue
66
Cost of Revenue
28
Gross Profit
38
Gross Margin
57.2%
Operating Income
4
Operating Margin
6.7%
Net Income
15
Net Margin
22.3%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
17
EBITDA Margin
25.0%